
Communication from QED Therapeutics
2020-03-24Global
QED is actively assessing the impact that COVID-19 may have on the work in place and wants to assure patients and families that they are committed to moving forward with the program to develop Infigratinib as an option for children with achondroplasia.
Creation of clothing line for bone dysplasias - Body measurements questionnaire
2020-01-19Global
A partnership between a patient organization with a textile professional from the north of Portugal is heading to create a clothing line for people with bone dysplasias/short stature.

Linguistic review of a questionnaire on achondroplasia
2019-09-20Global
There are more than 7000 languages in the world, but we need the be able to read and understand the same document when this is translated. We have supported a multinational project on validating the linguistic aspects of a questionnaire on achondroplasia in 15 countries.
A population-based study of achondroplasia in Europe
2019-09-09Global
The largest European population-based epidemiological study on achondroplasia was published with data provided by 28 registries in Europe, with cases reported between 1991-2015.

Do you want to volunteer?
2019-08-02Global
Beyond Achondroplasia has nearly 2 million views from 207 countries. It was started as a blog in April 2013 and it was done by me only, after work and weekends, until 2017. And since then, fantastic people started to support by volunteering and made it possible the creation of this multilingual platform.

Pfizer acquired Therachon. And now what to expect?
2019-05-14Global
Pfizer announced on the 9th May 2019 that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS).